Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A two-month, multi-center, randomized, double-blind, placebo-controlled hepatic safety study of ubrogepant in healthy volunteers

Trial Profile

A two-month, multi-center, randomized, double-blind, placebo-controlled hepatic safety study of ubrogepant in healthy volunteers

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 23 Dec 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ubrogepant (Primary)
  • Indications Migraine
  • Focus Adverse reactions
  • Most Recent Events

    • 23 Dec 2019 According to an Allergan media release, U.S. Food and Drug Administration (FDA) has approved a New Drug Application (NDA) for UBRELVY (ubrogepant) for the acute treatment of migraine with or without aura in adults.The FDA approval for UBRELVY is based on four clinical studies (ACHIEVE I, ACHIEVE II, UBR-MD-04 and 3110-105-002).
    • 04 Dec 2019 According to an Allergan media release, FDA action on New Drug Application (NDA) expected in December 2019.
    • 19 Sep 2019 Safety results (n=516) published in the Cephalalgia.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top